A Comparison of US Clinical Laboratory Chlamydia and Gonorrhea Testing Practices Before and After the 2014 Centers for Disease Control and Prevention Testing Recommendations.
A Comparison of US Clinical Laboratory Chlamydia and Gonorrhea Testing Practices Before and After the 2014 Centers for Disease Control and Prevention Testing Recommendations.
复制标题
DOI：
10.1097/olq.0000000000001299
复制
发表时间：
2021-06-01
影响因子：
3.1
通讯作者：
Gaynor A
中科院分区：
文献类型：
--
作者：
Davis A;Gaynor A
对美国临床实验室进行了一项调查，以比较2013年沙眼衣原体/淋病奈瑟菌检测实践（2014年疾病控制和预防中心检测建议发布之前）与2015年C。沙眼衣原体/N.淋病检测实践。补充数字内容可在文本中找到。坚持推荐的实验室检测做法对于性传播感染的预防和控制至关重要。本文的目的是比较2013年更新的2014年美国疾病控制和预防中心建议之前和2015年更新的建议之后美国临床实验室的沙眼衣原体（CT）和淋病奈瑟菌（NG）检测实践。共有236个临床实验室参与了关于其2013年和2015年CT和NG检测实践的调查，包括收集的标本类型和使用的检测方法的问题。从2013年到2015年，提供CT核酸扩增检测（NAAT）的实验室增加了5家，提供NG NAAT的实验室增加了5家。净增加了3个实验室接受尿液CT和NG NAAT，这是男性个体的首选标本类型。接受CT NAAT阴道拭子的实验室总数没有净增加（2013年和2015年n = 89），这是女性个体的首选标本类型，但接受NG NAAT阴道拭子的实验室增加了3个。开展NG药敏试验的实验室数量从2013年的100个减少到2015年的89个（χ2 = 1.07，P > 0.10）。在2013年至2015年的两年期间，测试实践没有重大变化。然而，也有一些小的变化，包括NAAT的使用增加，接受疾病控制中心和CT/NG的预防首选标本类型，以及制造商使用检测试剂盒的变化。
A survey of clinical laboratories in the United States was conducted to compare 2013 Chlamydia trachomatis/Neisseria gonorrhoeae testing practices (before the release of the 2014 Centers for Disease Control and Prevention testing recommendations) with 2015 C. trachomatis/N. gonorrhoeae testing practices. Supplemental digital content is available in the text. Adherence to recommended laboratory testing practices is crucial for sexually transmitted infection prevention and control. The objective of this article is to compare Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing practices of US clinical laboratories in 2013 before the updated 2014 Centers for Disease Control and Prevention recommendations and in 2015 after the updated recommendations. A total of 236 clinical laboratories participated in surveys about their 2013 and 2015 CT and NG testing practices, including questions on specimen types collected and assays used. There was an increase of 5 laboratories offering CT nucleic acid amplification testing (NAAT) from 2013 to 2015 and an increase of 5 laboratories offering NG NAAT. There was a net increase of 3 laboratories accepting urine for CT and NG NAAT, the preferred specimen type for male individuals. There was not a net increase in the total number of laboratories accepting vaginal swabs for CT NAAT (n = 89 in 2013 and 2015), the preferred specimen type for female individuals, but there was an increase of 3 laboratories accepting vaginal swabs for NG NAAT. The number of laboratories performing NG susceptibility testing decreased from 100 in 2013 to 89 in 2015 (χ2 = 1.07, P > 0.10). There were no major changes in testing practices in the 2-year period from 2013 to 2015. However, there were some small shifts, including increases in the use of NAATs, acceptance of Centers for Disease Control and Prevention–preferred specimen types for CT/NG, and changes in usage of assays by manufacturer.